302 related articles for article (PubMed ID: 25159013)
1. Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?
Vis AN; van der Sluis TM; Al-Itejawi HHM; van Moorselaar RJA; Meuleman EJH
Urol Oncol; 2015 Jan; 33(1):7-15. PubMed ID: 25159013
[TBL] [Abstract][Full Text] [Related]
2. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth.
Krakowsky Y; Morgentaler A
Eur Urol Focus; 2019 Jan; 5(1):81-89. PubMed ID: 28753828
[TBL] [Abstract][Full Text] [Related]
3. Is the flare phenomenon clinically significant?
Bubley GJ
Urology; 2001 Aug; 58(2 Suppl 1):5-9. PubMed ID: 11502435
[TBL] [Abstract][Full Text] [Related]
4. Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?
Oh WK; Landrum MB; Lamont EB; McNeil BJ; Keating NL
Urology; 2010 Mar; 75(3):642-7. PubMed ID: 19962733
[TBL] [Abstract][Full Text] [Related]
5. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
6. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
7. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
8. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.
Uehara S; Yuasa T; Fujii Y; Yano A; Yamamoto S; Masuda H; Fukui I; Yonese J
BMC Res Notes; 2015 Aug; 8():335. PubMed ID: 26242866
[TBL] [Abstract][Full Text] [Related]
9. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
[No Abstract] [Full Text] [Related]
10. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
11. Does Exist a Differential Impact of Degarelix
Sciarra A; Busetto GM; Salciccia S; Del Giudice F; Maggi M; Crocetto F; Ferro M; De Berardinis E; Scarpa RM; Porpiglia F; Carmignani L; Damiano R; Artibani W; Carrieri G
Front Endocrinol (Lausanne); 2021; 12():695170. PubMed ID: 34194398
[TBL] [Abstract][Full Text] [Related]
12. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.
Seidenfeld J; Samson DJ; Hasselblad V; Aronson N; Albertsen PC; Bennett CL; Wilt TJ
Ann Intern Med; 2000 Apr; 132(7):566-77. PubMed ID: 10744594
[TBL] [Abstract][Full Text] [Related]
13. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
[TBL] [Abstract][Full Text] [Related]
14. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
Pedraza R; Kwart AM
Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
[TBL] [Abstract][Full Text] [Related]
15. The role of LHRH antagonists in the treatment of prostate cancer.
Crawford ED; Hou AH
Oncology (Williston Park); 2009 Jun; 23(7):626-30. PubMed ID: 19626830
[TBL] [Abstract][Full Text] [Related]
16. Hormone therapy of prostatic bone metastases.
Huben RP
Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
[TBL] [Abstract][Full Text] [Related]
17. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
[TBL] [Abstract][Full Text] [Related]
18. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist in patients with prostate cancer.
Bong GW; Clarke HS; Hancock WC; Keane TE
Urology; 2008 Jun; 71(6):1177-80. PubMed ID: 18279929
[TBL] [Abstract][Full Text] [Related]
19. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
20. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]